Articles in PresS. Am J Physiol Endocrinol Metab - Semantic Scholar

24 downloads 0 Views 818KB Size Report
Dec 15, 2015 - Keywords: POU4F2/Brn-3b, transcription factor, glucose intolerance, GLUT4. 18. 19. 20. Articles in PresS. Am J Physiol Endocrinol Metab ...
Articles in PresS. Am J Physiol Endocrinol Metab (December 15, 2015). doi:10.1152/ajpendo.00211.2015 1

Profound hyperglycemia in knockout mutant mice identifies novel function for POU4F2/Brn-3b in regulating

2

metabolic processes

3 4

Stavroula Bitsi1, Houda Ali1, Lauren Maskell1, Samir Ounzain1,3, Vidya Mohamed-Ali2 and Vishwanie S. Budhram-

5

Mahadeo1*

6 7

1

8

2

9

3

Medical Molecular Biology Unit, UCL Institute of Child Health, London UK; Adipokines and Metabolism Research Group, Division of Medicine, University College London, UK.

Experimental Cardiology Unit, University of Lausanne Medical School, Switzerland

10 11

*

12

The Rayne Building, University College London, London WC1E 6JF. Tel (44) 2031082160; email: v.budhram-

13

[email protected]

To whom correspondence should be addressed: Vishwanie S Budhram-Mahadeo, Medical Molecular Biology Unit,

14 15 16

Running Title: Loss of Brn-3b linked to metabolic dysfunction

17 18

Keywords: POU4F2/Brn-3b, transcription factor, glucose intolerance, GLUT4

19 20

1 Copyright © 2015 by the American Physiological Society.

21

Abstract:

22

The POU4F2/Brn-3b transcription factor has been identified as a potentially novel regulator of key metabolic

23

processes. Loss of this protein in Brn-3b knockout (KO) mice causes profound hyperglycemia and insulin resistance

24

(IR), normally associated with type II diabetes (T2D), whilst Brn-3b is reduced in tissues taken from obese mice fed

25

on high-fat diets (HFD), which also develop hyperglycemia and IR. Furthermore, studies in C2C12 myocytes show

26

that Brn-3b mRNA and proteins are induced by glucose but inhibited by insulin, suggesting that this protein is itself

27

highly regulated in responsive cells. Analysis of differential gene expression in skeletal muscle from Brn-3b KO mice

28

showed changes in genes that are implicated in T2D such as increased glycogen synthase kinase-3 beta (GSK3β) and

29

reduced GLUT4 glucose transporter. The GLUT4 gene promoter contains multiple Brn-3b binding sites and is directly

30

transactivated by this transcription factor in co-transfection assays whereas chromatin immunoprecipitation (ChIP)

31

assays confirm that Brn-3b binds to this promoter, in-vivo. In addition, strong correlation between GLUT4 and Brn-3b

32

in Brn-3bKO tissues or in C2C12 cells strongly supports a close association between Brn-3b levels and GLUT4

33

expression. Since Brn-3b is regulated by metabolites and insulin, this may provide a mechanism for controlling key

34

genes that are required for normal metabolic processes in insulin-responsive tissues and its loss may contribute to

35

abnormal glucose uptake.

36 37

2

38

Introduction:

39

Metabolic homoeostasis is achieved by the coordination of complex and highly regulated processes that involve

40

crosstalk between different tissues (36). Many of these changes are mediated by circulating metabolites such as

41

glucose, which drive genetic changes in different tissues, thereby maintaining blood glucose levels within narrow

42

functional ranges. Under normal conditions, elevated blood glucose causes increased insulin secretion by the pancreas,

43

which facilitates glucose uptake, in responsive tissues, but inhibits gluconeogenesis and lipolysis in the liver and

44

adipose tissue (9). However, deregulation of one or more of these processes can cause elevated blood glucose

45

(hyperglycemia), which is characteristic of type II Diabetes Mellitus (T2D). Uncontrolled hyperglycemia can drive

46

pathophysiological changes such as inflammation and atherosclerotic plaque formation in the vasculature but also

47

contribute to the development of cardiovascular, renal and neuropathic diseases (2; 14; 15; 21; 22). However, the

48

molecular mechanisms that drive early pathological changes are not fully elucidated.

49

In post-prandial state, skeletal muscles and adipose tissues are responsible for the majority of glucose utilisation and

50

this is facilitated by insulin-responsive glucose transporters such as GLUT4, which are translocated from intracellular

51

vesicles to the plasma membrane where they facilitate glucose uptake from the bloodstream (27). Hyperglycemia and

52

T2D are often associated with insulin resistance, whereby normally insulin-sensitive tissues fail to respond to increase

53

circulating insulin (19; 36). Although these complex effects may be attributable to multiple factors, reduced GLUT4

54

expression has been implicated in impaired glucose responses and insulin resistance (13; 23; 27). In this regard,

55

disruption of one allele in heterozygote (GLUT4+/-) mutants has been sufficient to cause peripheral insulin resistance

56

(32). Furthermore, GLUT4 gene transcription is dynamically regulated by feeding in rodent models of streptozocin-

57

induced diabetes since fasted animals showed significant reduction of GLUT4 mRNA in adipose tissues, which was

58

rapidly reversed upon re-feeding (20; 34). Therefore, transcription factors that regulate GLUT4 expression, in a tissue-

59

specific manner, will be important for controlling metabolic processes in insulin-dependent tissues and may contribute

60

to initiation or progression of dysfunction/disease (18; 24).

61

The POU4F2/Brn-3b transcription factor (Brn-3b), which belongs to subclass IV of POU homeodomain proteins, is

62

characterised by the highly conserved DNA binding POU (Pit-Oct-Unc) domain(7) that binds to regulatory regions of

63

target genes, thereby controlling the rate of transcription by RNA pol II enzyme. The gene encoding Brn-3b consists

64

of two exons separated by an intron, which can give rise to distinct protein isoforms that are completely conserved in

65

the DNA binding C’ terminus but differ in N’terminal domain(26; 28). Thus, the shorter Brn-3b(s) protein is encoded 3

66

by exon 2 only, whereas Brn-3b(l) protein is encoded by exons 1+2 on therefore contains an additional N’ terminal

67

domain, which is not found in Brn-3b(s) (3; 8). However, the functions of distinct isoforms are still to be elucidated.

68

Brn-3b mediates diverse effects on cell fate by regulating the expression of multiple target genes but these are highly

69

dependent upon the cell types and/or growth conditions. For instance, Brn-3b can transactivate cell cycle proteins

70

cyclin D1/CDK4 (3) in epithelial cells and, as such, has been implicated in some cancers, where elevated Brn-3b

71

enhances cell proliferation and tumour growth (5; 7; 17). However, Brn-3b also confers drug resistance and migratory

72

potential after chemotherapeutic treatment by driving expression of other target genes such as the small heat shock

73

protein, HSP27, which protects cells under these conditions (6; 33). On the other hand, Brn-3b is essential for survival

74

and specification of retinal ganglion cells (RGC), since KO mutant mice are blind due to loss of RGC after birth (12;

75

26). However, if co-expressed with growth inhibitory p53 protein, Brn-3b can promote apoptosis by interacting and

76

cooperating with p53 to increase transcription of pro-apoptotic target genes e.g. Bax and Noxa. As such, it is crucial to

77

analyse the effects of this transcriptional regulator in the context of cell/tissue specific effects in order to determine its

78

mechanism of action on cell growth, behaviour or fate.

79

More recently, Brn-3b was identified as the only transcription factor to show significant changes in skeletal muscle

80

taken from subjects after 2 months of endurance training, when comparing gene expression in subjects with high or

81

low post-training insulin sensitivity(37). The results of these microarray analyses suggested that Brn-3b may be

82

important for controlling gene expression and function in metabolically active tissues also and lead us to hypothesize

83

that this transcription factor may regulate genes that control important metabolic processes.

84

These studies report on the expression of Brn-3b in insulin responsive tissues and investigate how loss of this

85

transcription factor affects metabolic function in Brn-3bKO mutant mice. Furthermore, the regulation of Brn-3b

86

expression in response to glucose and insulin have been characterised using the skeletal myoblast derived cell line,

87

C2C12. Finally, analysis of gene expression changes upon loss of Brn-3b has identified potential target genes such as

88

GLUT4, which may be regulated by this transcription factor in skeletal muscle and adipose tissues. The results, herein,

89

suggest that Brn-3b represents a novel regulator of target genes that are important for controlling metabolic function

90

and glucose homeostasis in insulin-responsive tissues.

91

4

92

Results:

93

Brn-3bKO mutant mice develop increased body weight and glucose intolerance

94

Casual observation of differences in the size of Brn-3b KO mice compared with WT littermates, led us to undertake

95

longitudinal studies to compare body weight (BW) over time (>12 months). Results showed that mutant mice had

96

consistently higher BW when compared with WT controls [Fig1A(i)] although there were no significant changes in

97

body length (e.g. Brn-3b KO ~ 9.3+/-0.05 cm VS WT females ~9.1+/-0.1 cm). Closer inspection showed increased

98

visceral fat deposits in the abdomen of Brn-3b KO mutants compared with littermate controls [Fig1A(ii)]. To test if

99

changes in body weight were caused by differences in calorie consumption, food intake was closely monitored for WT

100

and Brn-3b KO mutants fed on a high-fat diet (HFD) (see methods) and used to determine caloric intake. Fig 1A(iii)

101

showed that there were no statistically significant differences in consumption by KO mutants and WT controls

102

suggesting that increased body weight in Brn-3b KO mutants may result from potential changes in metabolic

103

processes. Since Brn-3b was shown to be differentially expressed in skeletal muscle of insulin responsive subjects

104

(37), we next tested for changes in glucose handling in Brn-3b KO mutants by undertaking glucose tolerance tests

105

(GTT). Therefore, Brn-3bKO and WT control mice were fasted for 12h and blood glucose levels were measured at

106

baseline, after which a glucose bolus was administered intraperitoneally. This was followed by half hourly blood

107

glucose measurements, up to 120 min. The results (Fig1B) showed no significant differences in blood glucose

108

between KO and WT mice at baseline (t=0) but marked differences were evident after administration of the

109

intraperitoneal glucose bolus. As expected, WT mice showed increased blood glucose at 30 mins, which decreased by

110

60 min and returned to baseline by 120 min. However, Brn-3b KO mice had significantly higher blood glucose levels

111

at 30min, which continued to rise at 60 min and remained significantly elevated after 120 min.

112 113

ELISA assays were used to examine insulin levels in serum collected at baseline and after 120 min. Although baseline

114

serum insulin levels in the mutant animals were slightly higher than WT, this was not statistically significant.

115

However, at the end of experiments (120 min), serum insulin was significantly higher in Brn-3b KO mutants when

116

compared with controls (Fig 1C). The observed hyperglycemia, accompanied by increased insulin levels, in mutant

117

mice suggested changes in metabolic processes such as insulin production or glucose uptake by insulin-responsive

118

tissues e.g. skeletal muscle, adipose tissue and liver. However, since Brn-3b expression was not previously

119

investigated in such tissues, western blot analyses were carried out using protein extracts from relevant issues

120

including pancreas, skeletal muscle, liver and adipose tissue. Fig 1D shows that Brn-3b was not detectable in pancreas 5

121

when significant levels were observed in insulin responsive tissues such as skeletal muscle and liver. The shorter Brn-

122

3b(s) isoform was more abundant in skeletal muscle whilst the longer Brn-3b(l) isoform was predominant in the liver

123

(Fig 1D) and adipose tissues (fig 2B). Although the potential roles for these distinct isoforms are unclear at present,

124

high Brn-3b expression in insulin responsive tissues such as skeletal muscle may suggests that persistent

125

hyperglycemia and insulin resistance in Brn-3b KO mutants are likely to be associated with defects in metabolically

126

active tissues rather than the pancreas, in which Brn-3b is not readily detected.

127 128

Brn-3b is reduced in insulin responsive tissues of WT mice fed on a diet with high saturated fat content:

129

Since loss of Brn-3b was associated with increased body weight and hyperglycemia, we considered if reduction of this

130

protein may be linked to diet induced obesity, which can also cause hyperglycemia and insulin resistance in rodent

131

models (38). To test this hypothesis, we generated and analysed a diet-induced obese mouse model in which WT mice,

132

fed on diet containing 60% saturated fat (HFD) for >12 weeks, were compared with control mice fed on normal diet

133

(ND). Most of the mice fed on HFD developed significant increase in BW when compared with age-matched controls

134

fed on ND. However, one animal fed on ND developed obesity, whereas one animal fed on HFD did not show

135

increased BW. Since these studies aimed to analyse the link between body weight and Brn-3b, these 2 mice were

136

excluded. At the end of these studies, GTT was undertaken on fasted mice to analyse blood glucose levels at baseline

137

(time 0) and then at 30, 60 and 120 min after administration of a glucose bolus. Although there were no significant

138

differences in blood glucose or serum insulin levels, at baseline between these groups (fig 2A), differences were

139

detected after 120 min when animals fed on ND showed an expected drop in blood glucose and serum insulin, similar

140

to baseline levels. However, animals fed on HFD demonstrated significantly elevated blood glucose and this was

141

associated with increased serum insulin levels Fig 2A(ii +iii), similar to the effect seen in Brn-3bKO mutants.

142

To examine potential links between changes in Brn-3b expression and development of pathophysiological effects in

143

these mice, we analysed for protein expression in insulin responsive tissues taken from mice fed on HFD or ND.

144

Analyses were carried out using skeletal muscle, which contributes to postprandial glucose uptake and adipose tissue,

145

which was considerably increased in animals fed on HFD. Fig 2B (i) shows protein levels in skeletal muscle and as

146

expected, Brn-3b(s) was highly expressed in tissues taken from ND fed mice but was significantly reduced in those

147

fed on HFD (ii). Adipose tissues expressed both Brn-3b isoforms but with higher levels of Brn-3b(l) detected in mice

148

fed on ND [fig 2B (iii)]. However, both isoforms were significantly reduced in tissues from HFD fed mice. These

6

149

results suggest that Brn-3b proteins are highly regulated in such metabolically active tissues and its reduction may

150

contribute to hyperglycemia observed in obese WT animals or in KO mutants.

151 152

Brn-3b expression is regulated by glucose and insulin in C2C12 myoblasts.

153

Since loss or reduction of Brn-3b was associated with high serum insulin and hyperglycemia, we next tested if Brn-3b

154

expression was affected by glucose and/or insulin in C2C12 myoblasts. Therefore, cells were either grown in medium

155

lacking glucose (NG); NG media supplemented with 25mmol glucose in the absence of insulin (NG-GLU); or with

156

added insulin (NG-GLU-INS). Control cells were grown in full growth medium (FGM). Fig 3A shows that Brn-3b

157

mRNA was reduced in cells grown in glucose-free medium and this was restored upon addition of 25 mmol glucose

158

(fig 4A), whereas chronic insulin treatment (10nmol for 24h) down-regulated Brn-3b mRNA, although insulin had no

159

effect at early time points (1 or 4h) (data not shown). These results were confirmed by immunoblotting to analyse

160

changes in protein levels. Although both Brn-3b isoforms were detectable in these cells, Brn-3b(s) was more abundant

161

than Brn-3b(l) (fig 4B), which is similar to previous data showing that Brn-3b(s) was the primary isoform in skeletal

162

muscle [fig 2A(ii)]. Cells that were grown in NG medium had reduced levels of both proteins, with Brn-3b(l) being

163

undetectable. Brn-3b(s) levels for restored and sustained by adding glucose to the NS medium, whereas addition of

164

insulin caused reduction of both Brn-3b isoforms.

165 166

Since Brn-3b expression was stimulated by glucose but reduced by insulin treatment, we next tested if these effects

167

were mediated at the level of transcription of the Brn-3b promoter. Therefore, C2C12 myoblasts were transfected with

168

Brn-3b reporter construct, then transferred into different growth conditions. Cells were harvested after 24h and dual

169

luciferase assays were used to measure promoter activity. Fig 3C shows that Brn-3b promoter activity was

170

significantly repressed when cells were grown in medium lacking glucose (NG) compared with FGM, whereas

171

addition of 25mM glucose was sufficient to increase promoter activity (>60 fold) compared with NG. However the

172

promoter was repressed by insulin. These results suggest that Brn-3b expression is highly regulated by glucose and

173

insulin in skeletal muscle.

174 175 176

Gene expression changes associated with loss of Brn-3b in skeletal muscle:

177

To identify gene expression changes in Brn-3bKO mice that might contribute to glucose intolerance, the disease-

178

focused RT² Profiler™ PCR 337021 Array was screened with cDNA synthesised using RNA extracted from skeletal 7

179

muscle taken from mutant mice or age-matched WT littermates(see methods). Table 1 shows a selection of genes that

180

were either over-expressed or under-expressed in Brn-3bKO mutants compared with WT controls. To validate

181

changes in selected genes, qRT-PCR was carried out using RNA from skeletal muscle taken from independent Brn-

182

3bKO or WT mice. Figure 4 shows that statistically significant changes were reproduced for glycogen synthase kinase

183

3 beta (GSK3β) mRNA, which was increased in Brn-3b KO mutants, whereas angiotensin-1 converting enzyme

184

(ACE) and the solute carrier family 4 glucose transporter (GLUT4) were both reduced in mutant tissue. However, the

185

expected changes in other genes were not significant or reproducible suggesting that GSK3β, ACE and GLUT4 may

186

be closely linked to Brn-3b expression.

187

Brn-3b binds to and activates the insulin-responsive glucose transporter, GLUT4:

188

The profound dysfunction in glucose handling observed in Brn-3b KO mutants was similar to impaired glucose

189

response and insulin resistance reported for GLUT4(+/-) or

190

might affect glucose uptake by regulating expression of this transporter. Genomatix Transfac analysis identified

191

multiple V$BRNF sites in the mouse GLUT4 promoter sequences that could act as potential binding sites for Brn-3b

192

transcription factor (fig 5A). These were clustered in two regions that were either proximal to the coding sequence

193

(indicated by p1 and p2) and distal sites (p3-p4). Therefore we tested if Brn-3b regulated transcription of this

194

promoter, co-transfection studies were carried out, in which the GLUT4 luciferase reporter was co-transfected with

195

different concentrations of Brn-3b expression vectors, into C2C12 cells. Results of the luciferase assays showed that at

196

1:1 ratio, Brn-3b transactivated the promoter by >4 fold but promoter activity was significantly enhanced (>12 fold)

197

when Brn-3b was increased to 2:1 (Fig 5B), confirming that Brn-3b does indeed, regulate GLUT4 promoter activity.

198

Since there were multiple potential binding sites spanning relatively large regions of the GLUT4 promoter, it was not

199

feasible to undertake site directed mutagenesis to identify specific site(s) that were required for Brn-3b-mediated

200

promoter activity. Therefore, to test if Brn-3b binds directly to the GLUT4 promoter in-vivo, in intact cells, we carried

201

out chromatin immunoprecipitation (ChIP) assays (26), in which Brn-3b Abs were used to immunoprecipitate the

202

protein bound to chromatin in intact C2C12 cells. GAPDH antibody was used as a negative control for binding

203

specificity. ChIP DNA isolated using Brn-3b Ab or GAPDH Ab control were used for PCR with primers designed to

204

amplify the two regions of GLUT4 promoter that were enriched for Brn-3b binding sites i.e. the proximal sites

205

(primers 1+2) or distal sites (primers 3+4) and the PCR products were resolved and 2% agarose gel. As shown in Fig

206

5C, amplification with primers 1+2 produced ~500 bp products, which was observed in the positive control (input)

(-/-)

mutants (13; 23). We therefore considered if Brn-3b

8

207

sample and ChIP DNA immunoprecipitated with Brn-3b Ab but not control Ab. However, although primers 3+4 gave

208

rise to ~350 bp products with the input DNA, no significant bands were produced when using the Brn-3b ChIP DNA.

209

These results suggest that Brn-3b binds directly to one or more of the sites in the proximal GLUT4 promoter to

210

activate gene expression.

211

To determine whether Brn-3b was necessary for maximal transcription of this gene, we next analysed for changes in

212

GLUT4 mRNA in insulin-responsive tissues such as skeletal muscle and adipose tissue, taken from mutants or age-

213

matched WT controls. Therefore, RNA from Brn-3b KO or WT tissues was used for cDNA synthesis and

214

quantification of GLUT4 transcripts using qRT-PCR whereas whole-cell protein extracts were used for immunoblots.

215

Fig 5D (i) shows that GLUT4 mRNA was significantly lower in skeletal muscle taken from Brn-3b KO mutants when

216

compared with levels in WT tissues, confirming that Brn-3b is necessary for transcription of this gene. To test if

217

reduced GLUT4 transcripts in Brn-3b KO mutants also affected protein levels, immunoblotting was carried out using

218

total cellular protein, extracted from insulin-responsive tissues from Brn-3b KO and WT controls. The representative

219

immunoblots shown in Fig 5D (ii) shows that the GLUT4 protein was reduced in Brn-3b KO adipose tissues, with ~

220

50% less protein, when compared with controls (iii).

221

We next tested if overexpressing Brn-3b affected basal GLUT4 protein levels in myoblasts by transfecting C2C12

222

cells with an expression vector containing Brn-3b cDNA (at 1 µg or 2 µg). Untransfected control cells (C) or cells

223

transfected with the empty expression vector (V) were used as controls and after 48 hours, protein extracts from

224

transfected cells were used for immunoblotting to analyse changes in GLUT4 and Brn-3b expression. Fig 5E shows a

225

representative immunoblot from these experiments that demonstrated increased Brn-3b protein in cells transfected

226

with the Brn-3b expression vector, which correlated with significant up-regulation of GLUT4 protein, when compared

227

with control cells. Furthermore, regression analysis showed statistically significant correlation between Brn-3b

228

expression and GLUT4 mRNA expression in C2C12 cells that were grown under different conditions e.g. FGM, NG

229

or NG+glucose [Fig 5E(ii)]. These results strongly support Brn-3b as a key regulator of GLUT4 in relevant

230

cells/tissues.

231

Discussion:

232

Hyperglycemia, which is commonly associated with insulin resistance, T2D and obesity, can drive pathological

233

processes that contribute to comorbidities such as cardiovascular diseases, renal dysfunction and neurological damage

234

(1; 14; 29). These effects result from complex molecular changes that are triggered in different tissues, which lead to 9

235

the development and progression of such diseases but the factors to control such changes are not fully understood(36).

236

Hyperglycemia, insulin resistance and T2D are set to rise, in line with a predicted global obesity epidemic, which is

237

linked to dietary and lifestyle changes (11; 25; 36). Therefore, it is important to understand the molecular mechanisms

238

that drive pathological changes since this may help to identify strategies that could be used to block or reverse tissue

239

damage, thereby minimising morbidity and mortality.

240

In this regard, we have identified Brn-3b as a novel regulator of glucose homeostasis. The first evidence suggesting

241

that this transcription factor may be involved in regulating metabolic processes, was inferred from microarray

242

analysis, which showed that Brn-3b was significantly altered in skeletal muscle taken from individuals with high or

243

low insulin sensitivity, following endurance training (37). Results from our studies have shown that Brn-3b protein is

244

expressed in insulin-responsive tissues such as skeletal muscle, adipose tissue as well as in liver, but has not been

245

detected in the pancreas. Furthermore, higher body weight in constitutive Brn-3b KO mice are associated with

246

increased fat deposition in the abdominal cavity, despite no statistically significant changes in body length or

247

differences in calorie consumption, when compared with control mice. Brn-3b KO mutants also developed persistent

248

hyperglycemia, in the presence of high serum insulin levels, suggesting that the pancreas continues to produce insulin

249

and high blood glucose may be linked to defects in insulin responsiveness and/or glucose uptake in tissues such as

250

skeletal muscle and adipose tissues. In line with this, Brn-3b expression is also reduced in skeletal muscle and adipose

251

tissues taken from WT mice that develop obesity and hyperglycemia/insulin resistance after being fed on a high

252

saturated fat diet. These results suggest that Brn-3b is dynamically regulated in such tissues and that the metabolic

253

dysfunction in constitutive KO mutants may result from direct loss of this transcription factor in insulin responsive

254

tissues.

255

Two distinct Brn-3b isoforms have previously been described (3; 8) and we have shown that Brn-3b(s) is the

256

predominant isoform in skeletal muscle, whereas Brn-3b(l) is more abundant in liver and adipose tissues. Moreover

257

both isoforms are regulated in response to high-fat diet. Although the functions of these distinct isoforms are still to be

258

elucidated, both proteins can be regulated by similar signals but can also regulate each other’s expression (8; 17).

259

Therefore, it will be interesting to investigate potential tissue-specific effects for distinct Brn-3b isoforms in insulin

260

responsive tissues, in later studies.

261

These results have provided evidence to support potential roles for the Brn-3b transcription factor in controlling

262

metabolic function and have been reinforced by findings in C2C12 myoblast cell, which show that Brn-3b can, itself, 10

263

be regulated by insulin and metabolites such as glucose. In this regard, Brn-3b mRNA and proteins are reduced in

264

cells grown in low glucose media or in the presence of insulin but can be restored by addition of physiological levels

265

of glucose (25 mM). These effects are likely to be mediated at the level of transcription since low glucose or insulin

266

can repress the Brn-3b promoter, whereas addition of glucose strongly stimulated promoter activity. Such tight

267

regulation of Brn-3b by insulin and glucose indicate that this transcription factor will have important role(s) for

268

regulating genes associated with glucose uptake.

269

In line with this, analysis of differential gene expression in skeletal muscle taken from Brn-3bKO and WT mice have

270

identified changes in key genes that are associated with metabolic processes. For example, increased GSK3β in Brn-

271

3b KO tissues may contribute to insulin resistance by phosphorylating and inhibiting key molecules such as glycogen

272

synthase and insulin receptor substrate proteins and importantly, elevated GSK3β has been detected in skeletal muscle

273

of patients with T2D (10; 16; 30). On the other hand, reduced GLUT4 in tissues taken from Brn-3b KO may underlie

274

the glucose intolerance detected in these mutants since Brn-3b directly regulates transcription of GLUT4 receptor.

275

Multiple potential Brn-3b binding sites have been identified by bioinformatic analysis and reporter assays confirm that

276

increasing exogenous Brn-3b can strongly transactivate the GLUT4 promoter in C2C12 cells. The presence of

277

multiple sites, clustered in 2 regions of the GLUT4 promoter, meant that it has not been possible to use site directed

278

mutagenesis to identify the specific sequence(s) required for Brn-3b binding and promoter activation. However, ChIP

279

analysis has conclusively demonstrated that Brn-3b binds directly to the proximal sites in the GLUT4 promoter, in-

280

vivo, in intact myoblast cells. There is also strong evidence for significant correlation between Brn-3b and GLUT4

281

expression from in-vivo and in vitro studies. Thus, GLUT4 mRNA and protein are reduced in insulin responsive

282

tissues (skeletal muscle and adipose), taken from Brn-3b KO mutant and altered Brn-3b correlate well with GLUT4

283

expression in C2C12 myoblasts, grown under different conditions. In addition, overexpressing Brn-3b in C2C12 cells

284

is sufficient to increase basal GLUT4 levels.

285

These findings strongly suggest that Brn-3b may be a key regulator of GLUT4 expression in insulin responsive tissues

286

and that loss of this receptor may contribute, in part, to hyperglycemia and insulin resistance observed in Brn-3b KO

287

mutants or in obese mice with reduced Brn-3b expression. The GLUT4 transporter is important for insulin-mediated

288

glucose uptake in adipose tissues and skeletal muscle, which accounts for majority of post-prandial glucose utilisation

289

(27). Although GLUT4 translocation from intracellular vesicles to the cell membrane is an important mechanism for

290

regulating glucose uptake, changes in expression levels have also been implicated in inefficient glucose utilization. 11

291

Thus, reduced GLUT4 expression in heterozygote mice is sufficient to cause defective glucose handling since mutant

292

mice develop severe peripheral insulin resistance, which can be reversed by recapitulating expression in skeletal

293

muscle (32; 35). Although the relevance of reduced GLUT4 in humans with non-insulin-dependent T2D has been

294

brought into question more recently (31), the clear correlation between Brn-3b and GLUT4 expression in insulin

295

responsive tissues, in these studies, strongly suggest that this transcription factor will be important for regulating the

296

expression of this glucose transporter in different tissues. However, GLUT4 is likely to be one of multiple target genes

297

that are regulated by the Brn-3b transcription factor in insulin responsive tissue that give rise to the complex

298

phenotypes seen in the constitutive KO mutants.

299

Thus, Brn-3b represents a novel and important regulator of metabolic processes in insulin responsive tissues.

300

However, since its expression is also controlled by circulating levels of metabolites and insulin, this transcription

301

factor may act as part of a feedback loop that maintains glucose homoeostasis, under normal conditions.

302 303

Materials and methods:

304

General laboratory reagents- Merck (Nottingham, UK); Sigma (Dorset, UK) unless otherwise stated. Tissue culture

305

reagents/plastics: Gibco/Life Technologies (Paisley, UK); Nunc (Paisley, UK); Greiner (Stonehouse, Gloucester, UK)

306

or Corning (Scientific Laboratory Supplies, Nottingham, UK). Primary antibodies were sourced as follows: rabbit-

307

Brn-3b pAb (Abcam-Cambridge, UK); goat-Brn-3b pAB and goat-actin pAb (Santa Cruz Biotechnology Inc, USA);

308

β-tubulin mAb, (Merck Millipore, Darmstad, Germany); Glut4 (1F8) Mouse mAb; Cell Signalling Technology

309

(Danvers, MA, USA) and all secondary Ab (Dako, Cambridgeshire, UK). GLUT4 promoter, cloned in the pGL3

310

luciferase vector, was a generous gift from Prof M. Quon (University of Maryland, Baltimore) and Prof E. Karnieli,

311

(Rambam Medical Center; Haifa).

312

Methods: In vivo models: Studies using rodent models were undertaken in accordance with Home Office guidelines

313

(Animals Scientific Procedures Act 1986) and approved by local Ethics Review Board. C57BL/6J strain was used for

314

studies, with outbred C57BL6 mice obtained from Harlan UK and Brn-3b heterozygote mice used to generate Brn-

315

3bKO mutant mice and aged-matched wild-type (WT) littermates. For longitudinal studies (>1 year), experimental

316

animals were weighed monthly, whereas mice fed on high fat diet (HFD) or normal chow diet (ND) were weighed

317

weekly. Dissected tissues (e.g. skeletal muscle, liver, adipose tissue, pancreas) were either snap frozen (for subsequent

318

RNA/protein extraction) or fixed in 4% paraformaldehyde (PFA) and embedded for subsequent sectioning.

12

319

Glucose Tolerance Tests (GTT) and Serum Insulin measurement: For GTT, experimental animals were fasted for

320

12 hours and baseline blood glucose was evaluated using a glucometer. Glucose bolus (2mg glucose/g BW) was

321

administered by intraperitoneal injection and blood glucose recorded after 15, 30, 60 and 120 min. For serum insulin

322

measurements, whole blood was collected from saphenous vein at the start and end of experiments into serum

323

separator tubes [BD Microtainer® (Becton-Dickinson, Franklin Lakes, NJ, USA)]. Serum insulin levels were

324

measured using Mercodia Mouse Insulin ELISA kit, Upsalla, Sweden).

325

Calorie consumption: Calorie consumption was calculated by monitoring dietary intake and then using the known

326

caloric value of the feed to calculate intake. Briefly mice were housed in separate cages and the chow was weighed at

327

the start of experiments and this was repeated at the end of each week, before topping up or replacing the feed. This

328

was also measured if it was deemed necessary to top up on at other times. The differences in weight (grams) of the

329

feed at the start and end of the week were multiplied by the known caloric value (5.1 kcal/gram) to calculate calorie

330

consumption per week for each mouse. The mean and standard error of each group (n>5) were used to determine

331

differences in calorie consumption over time.

332

Cell culture and treatments: Skeletal muscle satellite cell-derived C2C12 myoblasts were maintained in full growth

333

medium (FGM) [Dulbecco’s Modified Eagle’s Medium (DMEM); 10% foetal bovine serum (FBS); 1%

334

penicillin/streptomycin], grown in 5% CO2 at 37°C. Cells plated onto 6-well (5× 105/well) or 12-well (105/well)

335

culture dishes were transfected or treated as specified. Free fatty acids (FFA) -unsaturated long chain oleic acid and

336

saturated palmitic acid were dissolved in ethanol and used to treat cells. Transfections was carried out using FugeneTM

337

(Promega, Hampshire, UK) as previously described (6; 33) and reporter assays using the Dual Luciferase Reporter

338

Assay System (Promega, Hampshire, UK).

339

RNA extraction, cDNA synthesis, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR):

340

Tissues homogenized in liquid nitrogen were resuspended in TRIZOL® (Invitrogen); C2C12 cells were harvested in

341

Trizol then processed according to the manufacturer’s protocol. DNAse1 treated RNA was used for cDNA synthesis

342

(RNA Superscript™II RT) (Invitrogen,Paisley,UK). QRT-PCR was performed on Opticon 2 DNA engine thermal

343

cycler (BioRad, UK), using SYBR Green master mix (Qiagen, UK) and Brn-3b primers (forward-

344

ATCGCCGAAAAGCTGGAT; reverse-TTCTCTTCTGTTTCTGCCTCTG or QuantiTect Assay primers (Qiagen,

345

Manchester, UK) for selected target genes. Variability between samples or adjusted using GAPDH and fold changes

346

calculated using 2-∆∆CT method (25).

13

347

PCR array analysis: cDNA from Brn-3b KO skeletal muscle and WT controls (see above) were used to screen the

348

Mouse Diabetes RT² (SAB BioSciences, Qiagen, West Sussex, UK), which facilities the screening of 84 genes

349

associated with onset, development and progression of diabetes. Quantitative PCR was undertaken according to the

350

manufacturers’ protocol using the Opticon 2 DNA thermal cycler and analysis done using PCR Array Data Analysis

351

Software https://www.qiagen.com/gb/products/genes and pathways/data-analysis.

352

Protein extraction and immunoblotting: Cells were harvested in Laemmli buffer; mouse tissues were pulverised in

353

liquid nitrogen then resuspended in Laemmli buffer and homogenised. Total protein extraction and polyacrylamide gel

354

electrophoresis (SDS-PAGE) carried out as described(4). Proteins were quantified using densitometry (Quantity One

355

Software-BioRad Laboratories, CA, USA) or Image-J and the invariant β-tubulin protein used to adjust for differences

356

in protein loading.

357

Chromatin Immunoprecipitation (ChIP) Assay was carried out as described by Lee et. al.(22) using anti-goat Brn-

358

3b Ab (Santa Cruz) to immunoprecipitate Brn-3b on chromatin in intact cells. Anti-GAPDH (Abcam) was used as

359

negative. Sonicated ChIP DNA was amplified with PCR primers 1+2 or 3+4, designed to amplify different regions of

360

GLUT4 promoter. Primer 1: CAGGTACACATGTAGTACACA; Primer 2:TGGCTGTTCTGGAACTCACT; Primer

361

3: CTTGAGTATACATGTGGCACAC; Primer 4: TGTCAGCTTCTTGATGGCATC.

362

Transient transfections and reporter assays: To analyse effects of Brn-3b on GLUT4 promoter activity in C2C12

363

cells, 5x104 cells/well (in 6 well plates) were co-transfected with GLUT4 reporter construct and Brn-3b expression

364

vector or control LTR, using FugeneTM reagent (Roche; UK). To analyse effects of glucose +/-insulin on Brn-3b

365

promoter activity, the Brn-3b reporter construct was transfected into C2C12 cells grown in FGM, NG or NG+ glucose

366

with/without insulin. Cells were harvested after 24h and promoter activity measured using Dual-Luciferase reporter kit

367

(Promega, UK) and TD-20/20 luminometer (Turner Designs).

368

Statistics: Statistical analysis was performed using Microsoft Excel or GraphPad Prism 6 (San Diego, CA, USA).

369

Parametric tests (paired t-test) or non-parametric tests (Mann-Whitney; Kruskal-Wallis followed by post-hoc analysis

370

(Dunn’s multiple comparisons test) were used to determine differences between independent samples.

371 372

Acknowledgements: This research was funded by the Dunhill Medical Trust (SA24/0712), British Heart Foundation

373

(PG/08/074/25533) and the Rosetrees Trust. We are grateful to Prof M. Quon, University of Maryland, Baltimore and

374

Prof E. Karnieli, Rambam Medical Center; Haifa for providing GLUT4 promoter constructs; to Gautam Mehta and

375

Katayoon Gardner for technical assistance. 14

376

Author Contributions: S.B., H.A., LM and S.O. undertook experiments to provide data included in the manuscript.

377

V.M-A contributed to discussion and reviewed data, V.B-M obtained funding, supervised the study design and the

378

research and wrote manuscript.

379

Conflict-of-interest: There is no conflict-of-interest associated with this study.

380

Abbreviations: Brn-3b (Brn-3b/POU4F2 transcription factor); POU (Pit-Oct-Unc); T2D (type II diabetes); GSK-3β

381

(glycogen synthase kinase); glucose transporter, GLUT4; PPARα (peroxisome proliferator activated receptor-α); RGC

382

(retinal ganglion cells); FFA (free fatty acids); FGM (full growth medium with glucose); NG (no glucose medium);

383

INS (insulin); GTT (glucose tolerance test); WT (wild type); KO (knockout).

384 385 386 387 388 389 390

Reference List 1. Belkina AC and Denis GV. Obesity genes and insulin resistance. Curr Opin Endocrinol Diabetes Obes 17: 47477, 2010. 2. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 120: S12-S17, 2007. 3. Budhram-Mahadeo V, Moore A, Morris PJ, Ward T, Weber B, Sassone-Corsi P and Latchman DS. The closely

391

related POU family transcription factors Brn-3a and Brn-3b are expressed in distinct cell types in the testis. Int J

392

Biochem Cell Biol 33: 1027-1039, 2001.

393

4. Budhram-Mahadeo V, Morris PJ and Latchman DS. The Brn-3a transcription factor inhibits the pro-apoptotic

394

effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding

395

Bax and p21(CIP1/Waf1). Oncogene 21: 6123-6131, 2002.

396

5. Budhram-Mahadeo V, Ndisang D, Ward T, Weber BL and Latchman DS. The Brn-3b POU family transcription

397

factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. Oncogene 18: 6684-6691, 1999.

398

6. Budhram-Mahadeo VS, Irshad S, Bowen S, Lee SA, Samady L, Tonini GP and Latchman DS. Proliferation-

399

associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells.

400

Oncogene 27: 145-154, 2008.

401 402

7. Budhram-Mahadeo VS and Latchman DS. Targeting Brn-3b in breast cancer therapy" . Expert Opin Ther Targets 10: 15-25, 2006.

15

403

8. Dennis JH, Budhram-Mahadeo V and Latchman DS. The Brn-3b POU family transcription factor regulates the

404

cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells. Oncogene 20: 4961-

405

4971, 2001.

406 407 408 409 410 411 412

9. Desvergne B, Michalik L and Wahli W. Transcriptional regulation of metabolism. Physiol Rev 86: 465-514, 2006. 10. Eldar-Finkelman H and Krebs EG. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci U S A 94: 9660-9664, 1997. 11. Freeman H and Cox RD. Type-2 diabetes: a cocktail of genetic discovery. Hum Mol Genet 15 Spec No 2: R202R209, 2006. 12. Fujita R, Ounzain S, Wang AC, Heads RJ and Budhram-Mahadeo VS. Hsp-27 induction requires POU4F2/Brn-

413

3b TF in doxorubicin-treated breast cancer cells, whereas phosphorylation alters its cellular localisation following

414

drug treatment. Cell Stress Chaperones 2011.

415

13. Giacchetti G, Faloia E, Taccaliti A, Morosini PP, Arnaldi G, Soletti F, Mantero F, Accili D and De PR. Decreased

416

expression of insulin-sensitive glucose transporter mRNA (GLUT-4) in adipose tissue of non-insulin-dependent

417

diabetic and obese patients: evaluation by a simplified quantitative PCR assay. J Endocrinol Invest 17: 709-715, 1994.

418

14. Goran MI, Ball GD and Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and

419 420

adolescents. J Clin Endocrinol Metab 88: 1417-1427, 2003. 15. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr. and Sowers JR.

421

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

422

Circulation 100: 1134-1146, 1999.

423

16. Henry RR, Ciaraldi TP, Mudaliar S, Abrams L and Nikoulina SE. Acquired defects of glycogen synthase activity

424

in cultured human skeletal muscle cells: influence of high glucose and insulin levels. Diabetes 45: 400-407, 1996.

425

17. Irshad S, Pedley RB, Anderson J, Latchman DS and Budhram-Mahadeo V. The Brn-3b transcription factor

426

regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo. J Biol Chem 279:

427

21617-21627, 2004.

428 429

18. Kadonaga JT. Regulation of RNA polymerase II transcription by sequence-specific DNA binding factors 1. Cell 116: 247-257, 2004.

16

430 431 432 433 434 435 436 437 438

19. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 106: 459-465, 2000. 20. Kahn BB, Charron MJ, Lodish HF, Cushman SW and Flier JS. Differential regulation of two glucose transporters in adipose cells from diabetic and insulin-treated diabetic rats. J Clin Invest 84: 404-411, 1989. 21. Kahn CR, Vicent D and Doria A. Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu Rev Med 47: 509-531, 1996. 22. Kamide K, Nagano M, Nakano N, Yo Y, Kobayashi R, Rakugi H, Higaki J and Ogihara T. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 9: 1165-1171, 1996. 23. Kouidhi S, Berrhouma R, Rouissi K, Jarboui S, Clerget-Froidevaux MS, Seugnet I, Bchir F, Demeneix B,

439

Guissouma H and Elgaaied AB. Human subcutaneous adipose tissue Glut 4 mRNA expression in obesity and type 2

440

diabetes. Acta Diabetol 2011.

441

24. Latchman DS. Gene Regulation: A eukaryotic perspective. 2002.

442

25. Lazar MA. How obesity causes diabetes: not a tall tale. Science 307: 373-375, 2005.

443

26. Lee SA, Ndisang D, Patel C, Dennis JH, Faulkes DJ, D'Arrigo C, Samady L, Farooqui-Kabir S, Heads RJ,

444

Latchman DS and Budhram-Mahadeo VS. Expression of the Brn-3b transcription factor correlates with expression of

445

HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter. Cancer Res 65:

446

3072-3080, 2005.

447 448 449 450 451 452 453 454 455 456

27. Leto D and Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol 13: 383-396, 2012. 28. Liu YZ, Dawson SJ and Latchman DS. Alternative splicing of the Brn-3a and Brn-3b transcription factor RNAs is regulated in neuronal cells. J Mol Neurosci 7: 77-85, 1996. 29. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA and Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens 2013: 653789, 2013. 30. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K and Henry RR. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 51: 2190-2198, 2002. 31. Pedersen O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS and Kahn BB. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 39: 865-870, 1990.

17

457

32. Rossetti L, Stenbit AE, Chen W, Hu M, Barzilai N, Katz EB and Charron MJ. Peripheral but not hepatic insulin

458

resistance in mice with one disrupted allele of the glucose transporter type 4 (GLUT4) gene. J Clin Invest 100: 1831-

459

1839, 1997.

460 461 462 463 464 465

33. Samady L, Dennis J, Budhram-Mahadeo V and Latchman DS. Activation of CDK4 Gene Expression in Human Breast Cancer Cells by the Brn-3b POU Family Transcription Factor. Cancer Biol Ther 3: 317-323, 2004. 34. Sivitz WI, DeSautel SL, Kayano T, Bell GI and Pessin JE. Regulation of glucose transporter messenger RNA in insulin-deficient states. Nature 340: 72-74, 1989. 35. Stenbit AE, Tsao TS, Li J, Burcelin R, Geenen DL, Factor SM, Houseknecht K, Katz EB and Charron MJ. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 3: 1096-1101, 1997.

466

36. Taubes G. Insulin resistance. Prosperity's plague. Science 325: 256-260, 2009.

467

37. Teran-Garcia M, Rankinen T, Koza RA, Rao DC and Bouchard C. Endurance training-induced changes in insulin

468 469 470

sensitivity and gene expression. Am J Physiol Endocrinol Metab 288: E1168-E1178, 2005. 38. Winzell MS and Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 Suppl 3: S215-S219, 2004.

471 472 473

18

474

Figure legends:

475

Fig 1: Metabolic dysfunction in Brn-3b KO mutant mice: A. (i) Change in body weight in Brn-3bKO mutants (red

476

line; n=5) compared with age-matched WT control littermates (blue; n=5). Weights were measured at monthly

477

intervals, for up to 14 mths. (ii) Representative images of abdominal viscera of 3 mth old Brn-3b KO and WT mice. *

478

indicates the increased fatty deposits around internal organs such as the kidney in Brn-3b KO mutants, which is not

479

seen in WT controls (iii) Graph showing calorie consumption by WT mice (dark grey) or Brn-3b KO mutant (light

480

grey). Values represent the mean (+/- standard error) of calorie consumption of 6 individual animals in each group

481

measured at weekly intervals. B. Comparison of blood glucose levels in Brn-3b KO mutant mice (red line) when

482

compared with WT controls (black line). After overnight fasting, baseline blood glucose was measured before

483

administration of peritoneal injection of glucose bolus after-image blood glucose levels were measured half hourly for

484

120 mins. Values represent the mean +/-SD of 6 animals. C. (i) Table showing serum insulin levels in WT or Brn-

485

3bKO mutant mice either at baseline (time 0) and at the end of experiments (120m). (ii) Graph showing mean (+/-SD)

486

of serum insulin levels in WT (dark grey) or mutants (light grey) at two different time points. *indicates statistically

487

significant differences (p3 months. Baseline measurement was

495

undertaken after 12 h fasting and before administration of glucose bolus, after which analyses were done at intervals

496

shown, for up 120 min. (ii) Table showing blood glucose and insulin at baseline (t0) and at the end of experiments

497

(120 m). (iii) graph showing mean (+/-SD) of serum insulin levels in animals fed on ND (dark grey) or HFD (light

498

grey) at two different time points. **indicates statistically significant differences ND control and HFD (n = 6).

499

(B) Representative western blot analysis showing Brn-3b expression in skeletal muscle (i) and adipose tissue (iii)

500

taken from groups of animals fed on normal diet (ND) or high fat diet (HFD). Arrows indicate the position of distinct

501

isoforms, Brn-3b(l) or (s) and β-tubulin blots show differences in protein loading. (ii) and (iv) show quantification of

502

changes in Brn-3b(s) protein in skeletal muscle adipose tissue taken from mice fed on normal diet (ND) or high-fat 19

503

diet (HFD). Values were normalised to β-tubulin in corresponding samples and represent the mean and standard error

504

from four independent animals. * Indicates statistically significant reduction (iii) Brn-3b expression in in Brn-3b

505

protein in tissues taken from animals fed on HFD compared with ND as determined by t-test (n>3).

506

Fig 3: Brn-3b expression is regulated by glucose and insulin in myoblasts derived C2C12 cells: A. Results of

507

qRT-PCR showing relative changes in Brn-3b mRNA in C2C12 grown in full growth medium (FGM); no glucose

508

medium (NG); with NG +25 mmol glucose without insulin (NG-GLU) or with insulin (NG-GLU-INS). Values

509

represent the mean and standard deviation of levels taken from in three independent experiments. Brn-3b levels were

510

adjusted with the house keeping gene, GAPDH.

511

B. Western blot analysis showing changes in Brn-3b protein in C2C12 cells grown in different media including full

512

growth medium of (FGM); no glucose (NG) or with glucose added at different concentrations (as shown). Left panels

513

represent protein levels in the absence of insulin, whereas right panels shows similar glucose levels but in the presence

514

of insulin. The two different isoforms of Brn-3b are indicated (< >) and levels of tubulin protein was used to adjust for

515

variation in protein loading.

516

C. Results of luciferase assays showing changes in activity of the Brn-3b promoter, transfected into C2C12 cells that

517

were treated as indicated. Values were equalized with renilla luciferase activity (internal control) and the data

518

represents mean (+/- SD) from at least 3 independent experiments. * and ** indicates statistically significance (p

WT Brn-3b KO

1

0.5

0

time 0

MW < 46 kD

(ii) 1.5

Pancreas

0

1

Muscle

(B)

*

Serum insulin levels (ug/L)

15

*

Liver

25

Blood glucose (mg/dL)

Body weight (g)

WT

(ii)

(A) (i)

120

Time after glucose bolus (min)

Brn-3b(s) >

< 30 kD

b-tubulin >

< 58 kD

Fig 2:Reduced Brn-3b expression in insulin-responsive tissues in animals fed on a high-fat diet correlates with obesity, hyperglycaemia and insulin resistance

Blood glucose (mg/dL)

25

HFD

20 15 10

ND

5

ND-m1 ND-m2 ND-m3 ND-m4 HFD – m1 HFD – m2 HFD – m3 HFD - m4

0

30

60

Insulin -t0 (ug/L) 0.41 0.35 0.51 0.54 0.39 0.43 0.31 0.53

BG -120 min (mg/dl) 4.9 7.1 4.1 6.5 27.7 23.1 21 15.8

Insulin -120 m (ug/l) 0.49 0.36 0.30 0.53 1.2 2.6 0.94 1.0

Skeletal muscle ND HFD

MW < 46 kD

Brn-3b(l) >

< 30 kD

Brn-3b(s) >

1.5 p = 0.001 1

* 0.5

0 ND

< 58 kD

b-tubulin >

HFD

Diet

Brn-3b(l) > Brn-3b(s) > b-tubulin >

Adipose tissue HFD ND

MW < 46 kD < 30 kD < 58 kD

Brn-3b(l) protein (adjusted with b-tubulin)

(iv)

(iii)

0.45 Brn-3b(l) 0.3

p = 0.01 *

0.15

0 ND

HFD

Diet

p=0.01 1.5

120

Time (min) (i)

BG -t 0 (mg/dl) 4.3 5.3 4.9 4.8 9.2 5.3 5.9 7.3

(ii)

0

(B)

(iii)

(ii)

Serum insulin (ug/L)

30

(i)

Brn-3b(s) protein (SkM) (adjusted with GAPDH)

(A)

** ND HFD

1 0.5 0 time 0

120

Time after glucose bolus (min)

Fig 3: Brn-3b expression is regulated by glucose and insulin in myoblasts derived C2C12 cells (B) (i)

(A)

+ Insulin

no Insulin

NG +Glu NG

FGM

46 kD >

NG +Glu

MW

NG

FGM

**

< Brn-3b (l) > 30 kD >

< Brn-3b(s)>

58 kD >

Brn-3b promoter activity (firefly luciferase activity)

4

*

** 3

2

1

Brn-3b protein (equalised with tubulin)

(ii)

(C)

2 1.5 1 0.5 0

Insulin

0 FGM

NG

NG+ GLU

NG+GLU+INS

FGM +

-

-

NS +

NS + Glu - +

Table 1

Fig 4:Brn-3b KO tissue display significant changes in key metabolic genes

Over-expressed in 3b KO vs WT (RT² Profiler PCR Array) Fold change

Cebpa CEBPa

Thymoma viral proto-oncogene

(+) 321

CCAAT/enhancer binding protein A (+) 35

Ide

Insulin degrading enzyme

(+) 24.9

Ppara

Peroxisome proliferator activated receptor alpha

(+) 17.9

Gsk3b

Glycogen synthase kinase 3 beta

(+) 12

Irs1

Insulin receptor substrate 1

(+) 7

Under-expressed in 3b KO vs WT (RT² Profiler PCR Array) Fold change

Gene Ace

Angiotensin 1 converting enzyme

(-) 12

Slc2a4

Solute carrier family 4 (GLUT4)

(-) 5

** 0.001

mRNA in sk muscles

Akt-2

0.012

2 (equalised with GAPDH)

Gene

WT

**

Brn-3b KO

1.5 0.016

**

1

0.5

0 Ace-1

Akt-2

CEBPa CEBPa

GLUT4

GSK3b GSK3b

PPAR-a PPAR-a

qRT-PCR validation of selected genes in skeletal tissue

Fig 5: Brn-3b can activate GLUT4 expression Mouse GLUT4 gene promoter (A) p3

(E) (i) Transfected C2C12 cells

p1

Brn-3b DNA C 1ug 2ug 2ug

1053 p2

p4

V

Brn-3b>

10

Input

b-tubulin>

3b Ab

GLUT4 >

Input



3b Ab

**

15

(ii)

500bp 

*

0 LTR

Input

-ve Ab



3b Ab

5

Glut4 mRNA expression

product size: ~550bp

M

GLUT4 promoter activity (Firefly luciferase)

M

(C)

(B)

-ve Ab

V$BRNF enriched between 1440-1656; 2466- 2993;

Brn-3b (2:1) Brn-3b (4:1) Expression vector

(ratio of Brn-3b to GLUT4 promoter)

300bp  product size: ~350bp

2.5 2.0 1.5 1.0

y=0.3057x+0.4777 R2= 0.563 p

1

0.4+/-0.21 0.5

Brn-3b(s) >

1.1+/-0.22

GLUT4>

< 50 kD

0

WT Skeletal muscle

3b KO

b-tubulin >

< 58 kD

GLUT4 protein (adjusted with b-tubulin)

GLUT4 mRNA

(equalised using GAPDH)

(D) (i)

WT

1

3bKO

p= 0.01 *

0.5

0 WT

Brn-3bKO

6